Physician profile
Robert Abrams
NPI 1457441750
$5,321.53
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,368 · 2020: $852 · 2021: $1,311 · 2022: $758 · 2024: $33.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,150.06 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $580.68 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.45 | 2019-2022 | |
| Insmed, INC. | $338.84 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $290.52 | 2019-2022 | |
| Novo Nordisk INC | $231.17 | 2019-2020 | |
| Abbvie INC. | $204.36 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $192.02 | 2020-2022 | |
| Gilead Sciences, INC. | $187.52 | 2019 | |
| Merck Sharp & Dohme LLC | $169.92 | 2019-2022 | |
| Genentech USA, INC. | $149.29 | 2019-2021 | |
| Mylan Specialty L.P. | $143.57 | 2019-2020 | |
| Eisai INC. | $140.93 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $140.37 | 2021-2022 | |
| Pfizer INC. | $139.03 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $135.82 | 2019-2020 | |
| Electromed, INC. | $105.32 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.60 | 2019-2022 | |
| Biogen, INC. | $86.98 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $72.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $51.63 | 2019 | |
| Sanofi Pasteur INC. | $50.15 | 2019-2020 | |
| Genzyme Corporation | $46.80 | 2019 | |
| Mallinckrodt Enterprises LLC | $34.72 | 2019 | |
| Sunovion Pharmaceuticals INC. | $31.67 | 2019 | |
| United Therapeutics Corporation | $26.86 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.50 | 2020 | |
| Amgen INC. | $19.86 | 2022 | |
| Kaleo, INC. | $18.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.